Medication info
Idalbi Tablet 40 mg (Azilsartan Medoxomil)

Idalbi Tablet 40 mg (Azilsartan Medoxomil)

Prescription medicationTablet
Ingredient · strength
Potassium Azilsartan Medoxomil›42.68mg / 1 tablet
Manufacturer / importer
Celltrion Healthcare Co., Ltd.
Appearance
White or nearly white, round tablet
Packaging
PTP packaging - 28 tablets/Alu-Alu[(14 X 2)]
Approval status
Active

MFDS item code 202303419 · Approved 2023.12.22 · Insurance code 693903710

Summary

Main use
Treatment of essential hypertension
Who uses it
Adults · Children
Adult dosage
1) Adults The recommended initial dose of this medicine is 40 milligrams once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to a maximum of 80 milligrams once daily. The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 4 weeks. If blood pressure is not controlled with this medicine alone, additional blood pressure-lowering effects may be achieved when it is used in combination with other antihypertensive agents [diuretics (e.g., chlorthalidone, hydrochlorothiazide) or calcium channel blockers]. 2) Elderly patients No initial dose adjustment is necessary when this medicine is administered to elderly patients aged 65 years or older. For very elderly patients (aged 75 years or older) who are at risk of hypotension, an initial dose of 20 milligrams may be considered. 3) Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Use with caution in patients with severe renal impairment and patients with end-stage renal disease (ESRD), as there is no experience with the use of this medicine in these patients. Azilsartan is not removed by hemodialysis. 4) Patients with hepatic impairment This medicine is not recommended in patients with severe hepatic impairment because it has not been studied in these patients. Experience with the use of this medicine in patients with mild to moderate hepatic impairment is limited; therefore, close monitoring is recommended, and an initial dose of 20 milligrams may be considered. 5) Patients with intravascular volume depletion In patients who are salt-depleted or may have volume depletion (e.g., those with vomiting or diarrhea, or those receiving high doses of diuretics), initiate treatment with this medicine under close medical supervision and consider an initial dose of 20 milligrams.
Children's dosage
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Celltrion Healthcare Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
View approved original text

Essential hypertension refers to a condition where blood pressure remains persistently high without a specific cause. This condition can impose a burden on the heart and blood vessels, increasing the risk of cardiovascular diseases. By treating essential hypertension, it is possible to maintain blood pressure within the normal range and reduce the risk of complications. This medication is used for essential hypertension.

Dosage and Administration

Adult dosage

1) Adults The recommended initial dose of this medicine is 40 milligrams once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to a maximum of 80 milligrams once daily. The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 4 weeks. If blood pressure is not controlled with this medicine alone, additional blood pressure-lowering effects may be achieved when it is used in combination with other antihypertensive agents [diuretics (e.g., chlorthalidone, hydrochlorothiazide) or calcium channel blockers]. 2) Elderly patients No initial dose adjustment is necessary when this medicine is administered to elderly patients aged 65 years or older. For very elderly patients (aged 75 years or older) who are at risk of hypotension, an initial dose of 20 milligrams may be considered. 3) Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Use with caution in patients with severe renal impairment and patients with end-stage renal disease (ESRD), as there is no experience with the use of this medicine in these patients. Azilsartan is not removed by hemodialysis. 4) Patients with hepatic impairment This medicine is not recommended in patients with severe hepatic impairment because it has not been studied in these patients. Experience with the use of this medicine in patients with mild to moderate hepatic impairment is limited; therefore, close monitoring is recommended, and an initial dose of 20 milligrams may be considered. 5) Patients with intravascular volume depletion In patients who are salt-depleted or may have volume depletion (e.g., those with vomiting or diarrhea, or those receiving high doses of diuretics), initiate treatment with this medicine under close medical supervision and consider an initial dose of 20 milligrams.

Children's dosage

The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus or newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Individuals allergic to the ingredients contained in this medication or pregnant women should not take it. Patients with diabetes or severe renal dysfunction should exercise caution as the concomitant use of this medication with certain drugs may be risky. Patients with significantly weakened heart or kidney function, patients with narrowed renal arteries, or patients with reduced blood volume should have their blood pressure and kidney function closely monitored when using this medication. There is a risk of excessively low blood pressure; thus, care should be taken for symptoms of hypotension, especially when first taking the medication. If such symptoms appear, the patient should lie down, rest, and contact medical services if necessary. This medication may increase potassium levels in the blood; therefore, if taken with potassium-sparing diuretics or potassium supplements, regular checks of potassium concentration in the blood should be conducted. There may be dizziness or drowsiness when driving or operating machinery, so caution is needed. Interactions with other medications may occur while using this medication; therefore, consultation with a physician or pharmacist is necessary, especially if taking lithium or non-steroidal anti-inflammatory drugs (NSAIDs). It is recommended that breastfeeding women avoid this medication and consider alternative medications if breastfeeding must continue. Overdose may result in hypotension and dizziness; if these symptoms occur, immediate medical assistance should be sought since they cannot be removed by dialysis. Store this medication out of reach of children and keep it in its original packaging, protected from light and moisture.

Side effects

  • Dizziness
  • hypotension
  • diarrhea
  • nausea
  • rash
  • itching
  • angioedema
  • muscle cramps
  • fatigue
  • peripheral edema
Show 33 more
  • increased serum creatine phosphokinase
  • increased serum creatinine
  • increased serum uric acid
  • headache
  • nasopharyngitis
  • chest discomfort
  • constipation
  • vomiting
  • bad breath
  • asthenia
  • dyspnea
  • dyslipidemia
  • hypercholesterolemia
  • gout
  • hyperkalemia
  • arthralgia
  • myalgia
  • musculoskeletal stiffness
  • increased aspartate aminotransferase
  • urinary tract infection
  • upper respiratory infection
  • acute kidney injury
  • diabetic nephropathy
  • dermatitis
  • hives
  • hair loss
  • subdural hematoma
  • irregular menstruation
  • exacerbation of hypertension
  • chest pain
  • palpitations
  • fainting
  • pre-syncope

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that protects from light and is best kept at room temperature between 1 to 30 degrees Celsius. Additionally, it should be stored in a place that avoids excessive moisture to maintain its effectiveness.

Appearance and packaging

Appearance

White or nearly white, round tablet

Package unit

PTP packaging - 28 tablets/Alu-Alu[(14 X 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.